LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

Relay Therapeutics Inc

Closed

SectorHealthcare

2.91 1.04

Overview

Share price change

24h

Current

Min

2.73

Max

2.93

Key metrics

By Trading Economics

Income

-1.1M

-77M

Sales

7.7M

7.7M

EPS

-0.455

Profit margin

-1,003.581

Employees

259

EBITDA

-1.2M

-85M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+389.51% upside

Dividends

By Dow Jones

Next Earnings

5 sie 2025

Market Stats

By TradingEconomics

Market Cap

-52M

502M

Previous open

1.87

Previous close

2.91

News Sentiment

By Acuity

50%

50%

166 / 382 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Relay Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 maj 2025, 20:33 UTC

Acquisitions, Mergers, Takeovers

Salesforce in Talks to Buy Informatica, Bloomberg Reports, Citing Sources

23 maj 2025, 21:57 UTC

Hot Stocks

Stocks to Watch: Apple, Booz Allen, Constellation Energy, Intuit -- WSJ

23 maj 2025, 21:15 UTC

Top News

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23 maj 2025, 21:04 UTC

Acquisitions, Mergers, Takeovers

Real-Estate Broker Douglas Elliman Could See Takeover Battle After Report of Bid -- Barrons.com

23 maj 2025, 20:56 UTC

Top News
Acquisitions, Mergers, Takeovers

Salesforce Back in Deal Talks With Informatica -- WSJ

23 maj 2025, 20:51 UTC

Top News

Boeing in Tentative Agreement to Pay $1.1 Billion to Avoid Trial for 737 MAX Crashes -- WSJ

23 maj 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

23 maj 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23 maj 2025, 20:41 UTC

Top News

Stocks Fall on Tariff Broadside, After Week of Bond Market Agita -- WSJ

23 maj 2025, 20:28 UTC

Top News

Trump Threatens EU With 50% Tariffs, Takes Aim at Apple; Nasdaq Drops -- WSJ

23 maj 2025, 20:06 UTC

Top News

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 5th Update

23 maj 2025, 20:06 UTC

Acquisitions, Mergers, Takeovers

Salesforce Stock Drops, Informatica Soars. A Deal May Be Back on the Table. -- Barrons.com

23 maj 2025, 19:50 UTC

Top News

Trump's Tariffs: Where Things Stand -- 16th Update

23 maj 2025, 19:28 UTC

Acquisitions, Mergers, Takeovers

Trump on Truth Social: 'Bulk of That Investment Will Occur in the Next 14 Months'

23 maj 2025, 19:28 UTC

Acquisitions, Mergers, Takeovers

Trump on Truth Social: 'This Will Be a Planned Partnership Between United States Steel and Nippon Steel'

23 maj 2025, 19:27 UTC

Acquisitions, Mergers, Takeovers

Trump on Truth Social: 'Proud to Announce That, After Much Consideration and Negotiation, US Steel Will REMAIN in America'

23 maj 2025, 19:20 UTC

Market Talk

Crude Futures Post Modest Weekly Losses -- Market Talk

23 maj 2025, 19:18 UTC

Market Talk

U.S. Natural Gas Futures End Week Unchanged -- Market Talk

23 maj 2025, 18:57 UTC

Top News

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23 maj 2025, 18:54 UTC

Top News

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- Update

23 maj 2025, 18:53 UTC

Top News
Acquisitions, Mergers, Takeovers

McDonald's Bids Goodbye to CosMc's, Its Space Alien-Themed Spinoff -- WSJ

23 maj 2025, 18:52 UTC

Acquisitions, Mergers, Takeovers

DDC Enterprise Issues 254,333 Class A Ordinary Shrs in Exchange for 21 BTC, Valued at About $2.28M in Current Market Price

23 maj 2025, 18:13 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

23 maj 2025, 18:13 UTC

Market Talk

Gold Trades Higher on Reminder of Risk -- Market Talk

23 maj 2025, 18:00 UTC

Top News

Apple's Stock Still Not Pricing in Trump's Demands - Heard on the Street -- WSJ

23 maj 2025, 17:51 UTC

Market Talk
Earnings

Workday Sees Higher Bar for Guidance -- Market Talk

23 maj 2025, 17:42 UTC

Top News

Dow Drops, Trump Threatens EU With 50% Tariffs, Takes Aim at Apple -- WSJ

23 maj 2025, 17:39 UTC

Market Talk

U.S. Oil Rig Count Falls to Lowest Level Since November 2021 -- Market Talk

23 maj 2025, 17:07 UTC

Top News

Trump's Tariffs: Where Things Stand -- 15th Update

23 maj 2025, 17:04 UTC

Market Talk
Earnings

Workday Appears to Have Upside Potential on Conservative Outlook -- Market Talk

Peer Comparison

Price change

Relay Therapeutics Inc Forecast

Price Target

By TipRanks

389.51% upside

12 Months Forecast

Average 14 USD  389.51%

High 23 USD

Low 4 USD

Based on 12 Wall Street analysts offering 12 month price targets forRelay Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

10

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

2.88 / 3.285Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

No Evidence

Sentiment

By Acuity

166 / 382 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.